LUMIBIRD: Q3 REVENUE - AGREEMENT SIGNED TO ACQUIRE THE CONTINUUM
PRODUCT RANGE FROM THE AMPLITUDE LASER GROUP
Lannion, October 21, 2024 – 5:55 pm
Q3 REVENUE
AGREEMENT SIGNED TO ACQUIRE THE CONTINUUM PRODUCT RANGE
FROM THE AMPLITUDE LASER GROUP
- Growth upturn in Q3 for the
Medical Division, stability for the Photonics
Division
- Signature of an agreement
with Amplitude Laser Group to acquire the Continuum range of
nanosecond lasers from its US subsidiary
The LUMIBIRD Group (FR0000038242 -
LBIRD), the European leader in laser technologies, recorded
revenues of €141.5m for the first 9 months of 2024, up +2% and
stable on a like-for-like basis. Revenues for the 3rd quarter
showed a clear upturn in growth for the Medical segment, at +8.0%,
and stability for the Photonics segment, at +0.2% on a reported
basis. The Group also announces the signature of an agreement with
Amplitude Laser Group for the acquisition of the Continuum
nanosecond laser product line, enabling Lumibird to enhance its
range for the scientific markets and strengthen its leadership of
the North American market.
Consolidated revenues
(unaudited)
Revenues (€M) |
2024 |
2023 |
Reported change |
Change at constant scope and exchange rates |
1st
quarter |
43.9 |
40.9 |
+7% |
+5% |
2nd
quarter |
54.1 |
56.3 |
-4% |
-7% |
3rd
quarter |
43.5 |
41.8 |
+4% |
+4% |
9 months |
141.5 |
139.0 |
+2% |
0% |
of which |
|
|
|
|
Photonics |
67.3 |
65.9 |
+2% |
-3% |
Medical |
74.2 |
73.0 |
+2% |
+3% |
By division
Over the first 9 months, the Photonics division
grew by +2% (-3.0% on a like-for-like basis) compared with the
first 9 months of 2023, with a 3rd quarter at €20.1m
(+0.2% and +0.0% on a like-for-like basis).
Sales for the 3rd quarter continued
to be driven by Defence/Space (up 30% at €8.9m) and Medtech (up 19%
at €2.4m). The Industrial & Scientific business (down 15% at
€6.0m) continued to suffer from weaker demand from end-users, while
the ETS (Environment, Topology and Security) business began to
recover, with a smaller fall (down 32% at €2.8m) than in the
previous quarter.
The Medical division returned to growth in the
3rd quarter (+8% to €23.4m), in line with the Group's
targets. Over 9 months, growth was up 2% at €74.2m, largely driven
by the laser treatment activity (up 6.5% at €58.5m), which
accounted for 79% of sales over the period.
By geographical area
The breakdown of 9-month sales by geographical
area is as follows:
Revenues (€M) |
Photonics |
Chg |
Medical |
Chg |
Europe |
40,0 |
20% |
25,0 |
4% |
Americas |
9,8 |
-23% |
20,9 |
2% |
Asia-Pacific |
10,6 |
-30% |
21,4 |
-3% |
Rest of the world |
6,8 |
49% |
7,0 |
5% |
Total |
67,3 |
2% |
74,2 |
2% |
Unaudited data
The strong growth of the Photonics division in
Europe remains linked to its activity in the Defence/Space and
Medtech markets, while the decline in the Americas and Asia-Pacific
is due to applications and systems in the Environment, Topography
and Security segment.
In the 3rd quarter, the Medical
division benefited from more buoyant markets in Europe (+12%
compared with the 3rd quarter of 2023) and Asia-Pacific
(+27% compared with the 3rd quarter of 2023), with the gradual
lifting of administrative obstacles in China in the second half of
2023.
As in previous years, Lumibird anticipates a
very high level of activity in the 4th quarter, and
confirms its sales growth target of over 5%, and its profitability
target of an EBITDA margin of over 16% as a percentage of
sales.
Lumibird announces that it has signed an
agreement with Amplitude Laser Group to acquire its nanosecond
laser product line under the Continuum brand and its associated
service business, representing sales of over €7m based on the
financial year ending 31 March 2024.
This acquisition should be completed in the next
few weeks. It will strengthen Lumibird's position, particularly
with US universities, in the field of nanosecond lasers. The
Powerlite ultra-high-energy solid-state lasers and the OPO, Horizon
and Slopo systems will strengthen Lumibird's product offering.
This acquisition will also generate industrial
synergies.
According to Marc Le Flohic, Chairman and CEO of
Lumibird: "The acquisition of the Continuum brand, which is
highly recognised by universities, will enable Lumibird to
strengthen its product range and increase its share of the
nanosecond solid-state laser market. This operation is not only
profitable, it is also in line with the Group's strategy of
strengthening our position in a recurring market and accelerating
the optimisation of the Group's industrial tools.”
Damien Buet, Chairman and CEO of Amplitude Laser
Group, said: "This transaction enables Amplitude to focus its
development on ultra-fast and very high-energy lasers for the US
and global markets. I would like to thank the Continuum teams for
their contribution to the Group in recent years. Lumibird's
acquisition will allow the Continuum range to accelerate its
development and provide our customers with an enhanced offering in
the field of solid-state nanosecond lasers. Amplitude will work
closely with Lumibird to ensure a smooth transition for all
stakeholders.”
Next information: publication
of 2024 FY revenues on 27/01/2025, after close of trading.
About Amplitude Laser Group
Amplitude Laser Group is a global leader in
ultrafast laser design and manufacturing, driving advancements in
industrial processes, medical treatments, and Nobel-caliber
science. With over 20 years of innovation, the group’s product
portfolio includes diode-pumped, fiber femtosecond, and
high-intensity Ti-Sapphire lasers. Amplitude is committed to
creating and developing innovative lasers, manufactured to the most
rigorous standards including ISO 9001 and ISO 13485.
https://amplitude-laser.com/
LUMIBIRD is one of the world's leading laser
specialists. With 50 years' experience and expertise in
solid-state, diode and fibre laser technologies, the Group designs,
manufactures and distributes high-performance laser solutions via
two divisions: Photonics and Medical. The Photonics Division
designs and produces components, lasers and systems for the defence
and space, environment, topography and safety, industrial and
scientific, and medtech markets. The Medical branch designs and
produces medical diagnostic and treatment systems for
ophthalmology.
The result of the merger in October 2017 between the Keopsys and
Quantel Groups, LUMIBIRD, with more than 1,000 employees and over
€203.6m in sales in 2023 is present in Europe, America and
Asia.
LUMIBIRD shares are listed in compartment B of Euronext
Paris. FR0000038242 -
LBIRD www.lumibird.com
LUMIBIRD has been a member of Euronext
Tech Leaders since
2022.
Contacts
LUMIBIRD
Marc Le Flohic
Chairman and Chief Executive Officer
Tel. +33(0) 1 69 29 17 00
info@lumibird.com |
LUMIBIRD
Sonia Rutnam
Chief Financial and Transformation Officer
Tel. +33(0) 1 69 29 17 00
info@lumibird.com |
Calyptus
Mathieu Calleux
Investor Relations
Tel. +33(0) 1 53 65 37 91
lumibird@calyptus.net |
This press release contains forward-looking
statements. These forward-looking statements represent trends or
objectives, as the case may be, and should not be construed as
forecasts of the Company's results or any other performance
indicator. These statements are by their nature subject to risks
and uncertainties as described in the Company's URD filed with the
Autorité des Marchés Financiers (under number D24-0239). These
statements do not therefore reflect the Company's future
performance, which may differ materially.
- 241021_Lumibird_CAQ3_2024_CONTINUUM _EN
Lumibird (EU:LBIRD)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Lumibird (EU:LBIRD)
Historical Stock Chart
Von Dez 2023 bis Dez 2024